Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 5/20 | 0.47 |
| ▸ | EHMT1 | Q9H9B1 | 5/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 4/20 | 0.41 |
| ▸ | FLT1 | P17948 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | KMT5A | Q9NQR1 | 2/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.36 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4793421 | 0.93 | NCF1 (0.49) | EHMT2EHMT1PDPK1KDRFLT1 | |
| SCHEMBL4979935 | 0.92 | PDE10A (0.45) | EHMT2EHMT1NCF1PDE10APDGFRB | |
| SCHEMBL4792601 | 0.89 | HTR1A (0.43) | EHMT2EHMT1KDRFLT1FGFR1 | |
| SCHEMBL5479282 | 0.88 | FLT1 (0.46) | PDPK1KDRFLT1FGFR1PDE10A | |
| SCHEMBL4975789 | 0.87 | FLT1 (0.44) | PDPK1KDRFLT1FGFR1PDE10A | |
| SCHEMBL4779758 | 0.85 | KDR (0.44) | PDPK1KDRFLT1FGFR1PDE10A | |
| SCHEMBL5653805 | 0.84 | PDGFRB (0.44) | EHMT2NCF1PDE10APDGFRBSLC2A1 | |
| SCHEMBL4981518 | 0.84 | NCF1 (0.55) | NCF1PDE10APDGFRBSLC2A1SLC2A2 | |
| SCHEMBL4984909 | 0.83 | PDE10A (0.50) | EHMT2EHMT1NCF1PDE10APDGFRB | |
| SCHEMBL5655080 | 0.80 | HTR1A (0.46) | EHMT2PDE10APDGFRBSCN9ASLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991531-A1 | CINNOLINE AND QUINOXALINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-12-13 | — | — | US | disclosed |
| WO-2007100880-A1 | CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007100880-A1 | CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | EHMT2 3772/4885EHMT1 3121/4885PDPK1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.